Dana-Farber Pathways: Innovation in Oncology Care Delivery

As the complexity and cost of cancer care increases, there is an urgent need to support and track clinical decision making, reduce unwarranted variation in patient care and optimize resource utilization. Through the development of evidence- and consensus-based, disease specific, dynamic clinical pathways (DCPs), Dana-Farber Cancer Institute has been able to leverage the expertise of clinicians and access to clinical trials in community-based clinical practice, where the majority of cancer care is delivered. Based on efficacy, toxicity and cost, pathways define a single preferred treatment for a given cancer diagnosis.